Can I buy Semaglutide online legally?

The short answer: in the US, UK, and EU, semaglutide is a prescription-only medicine. That means it cannot be legally purchased from an online vendor without a valid prescription issued by a licensed prescriber. There is no lawful over-the-counter or direct-to-consumer route, regardless of the country. What exists online beyond legitimate telehealth platforms are grey-market or counterfeit products, and the regulatory agencies covering each major jurisdiction have warned about them explicitly.

This piece breaks down the legal position by jurisdiction, explains what the grey-market supply actually looks like, and directs you toward the routes that are both legal and subject to quality oversight^[1].

United States: prescription-only, compounding rules changed

The FDA first approved injectable semaglutide (Ozempic) for type-2 diabetes in December 2017, and Wegovy (semaglutide 2.4 mg) for chronic weight management in June 2021. Both are Schedule-IV prescription medicines dispensed by licensed pharmacies against a valid prescription.

Between 2022 and early 2025, semaglutide appeared on the FDA drug-shortage list. During that window, compounding pharmacies could legally prepare versions of it under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. That window has closed. The FDA declared the semaglutide shortage resolved and began winding down enforcement discretion for large-scale compounding^[2]. Compounding pharmacies that continue to produce semaglutide copies at scale are now operating outside that permission, and the FDA has taken action against some of them.

The practical implication: if you are in the US and you see a website advertising injectable semaglutide without requiring a US-licensed prescriber's involvement, that product is operating outside the current regulatory framework. Branded Ozempic and Wegovy dispensed by a licensed pharmacy against a prescription from a US-licensed provider remains the lawful route.

United Kingdom: MHRA prescription-only, no authorised OTC route

In the UK, semaglutide is authorised by the MHRA under three brand names: Ozempic (injection, type-2 diabetes), Wegovy (injection, weight management), and Rybelsus (oral tablet, type-2 diabetes). All three are prescription-only medicines (POM) under UK law. They are not available over the counter. A UK-licensed prescriber must issue a prescription before any pharmacy, including an online pharmacy registered with the General Pharmaceutical Council, can dispense them.

The MHRA has issued guidance specifically to semaglutide prescribers and patients about safety and the importance of using authorised supply chains^[3]. The agency warns that products bought from unregulated online sources may be falsely labelled, contain incorrect doses, or be contaminated. Counterfeiting of GLP-1 class products has been an active enforcement concern in the UK.

UK patients who qualify on NHS criteria can access semaglutide via their GP or a specialist weight-management service. Those outside NHS eligibility can obtain a private prescription and use a GPhC-registered online pharmacy. Country-level access rules are tracked on the semaglutide regulation page and, for country-specific detail, on the UK regulation hub.

European Union: centrally authorised, prescription-only in all member states

The EMA has granted centralised marketing authorisations for all three semaglutide brands. Ozempic received EU authorisation in February 2018 for type-2 diabetes^[1]. Wegovy received authorisation in January 2022 for weight management^[4]. Rybelsus received authorisation in April 2020 for type-2 diabetes (oral). These authorisations are valid across all EU and EEA member states.

Prescription status across the EU is governed by national medicines agencies, but the centrally authorised products are classified as prescription-only in every member state we cover, including Denmark, Sweden, Norway, Germany, and the Netherlands. No member state has reclassified semaglutide as an over-the-counter product.

The EU supply has faced shortages since 2022 as demand exceeded manufacturing capacity. Those shortages do not create a legal grey zone. Purchasing from an unregistered online vendor in response to a shortage does not legalise the transaction under Directive 2001/83/EC.

What the grey market actually looks like

Despite the consistent legal picture across jurisdictions, a substantial grey market exists. It takes several forms: research-chemical websites labelling semaglutide 'for laboratory use only', telehealth platforms that issue prescriptions with no meaningful clinical assessment, overseas pharmacies shipping product without verifying foreign prescription requirements, and outright counterfeit product.

The research-chemical framing does not provide legal cover. If a product is sold for human administration, the 'for research use only' label on the packaging does not change its classification under medicines law in the US, UK, or EU. The quality concern is separate and compounds the legal one: products sold outside any pharmacopoeial framework have not been verified for identity, purity, or sterility. Counterfeit GLP-1 class products, including some falsely labelled as Ozempic, have been documented in multiple regulatory enforcement actions^[3].

The lawful routes

The legitimate path to semaglutide requires a prescription from a licensed prescriber in your jurisdiction. That can happen through several channels depending on where you are.

In the US: your primary care provider, an endocrinologist, or a telehealth platform that performs a genuine clinical evaluation and is staffed by US-licensed prescribers. Telehealth prescribing for GLP-1 drugs has expanded significantly, but the quality of clinical evaluation varies widely across platforms. A provider who issues a prescription without reviewing your medical history, current medications, and any contraindications is not meeting the standard of care.

In the UK: your GP (for NHS-eligible patients), an NHS specialist weight-management service (for obesity indication under NICE TA1026), or a private prescriber. Any online pharmacy you use should be registered with the GPhC.

In the EU: your general practitioner, an endocrinologist, or a diabetes specialist. Access conditions vary by member state for reimbursement, but the prescription requirement is universal. Consult a clinician who knows your health history before starting any GLP-1 class medicine.